News News

Sirnaomics June 03 Preview
June 3, 2019 Sirnaomics Counts on New RNA Technology to Fuel Wide-Ranging Cancer & Fibrosis Pipeline

While some RNA technology companies are still exploring the accompanying science, Sirnaomics, based in Gaithersburg MD with subsidiaries in Suzhou and Guangzhou, China, has already established 10 pre-clinical and clinical RNA based programs focused on oncology and fibrosis.

Sirnaomics News Placeholder 01
May 16, 2019 Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 ASCO Abstract

Sirnaomics announced the results showing STP705 inhibits the growth of HuCCt-1 (a human cholangiocarcinoma cell line) as a xenograft tumor in nude mice.

Sirnaomics News Placeholder 05
April 26, 2019 Sirnaomics Closes $48 Million Series C Financing to Develop RNAi Therapeutics

Sirnaomics has sealed the C2 round of financing for $22 million. This round of funding was led by CR-CP Life Sciences Fund, a Hong Kong based joint venture established by China Resources Group and Charoen Pokphand Group, two Asian conglomerates.

Sirnaomics News Placeholder 04
April 8, 2019 Sirnaomics to Present at World Orphan Drug Congress 2019

Sirnaomics announced that the Company’s management will present its platform technology and discuss the potential clinical utility of RNAi therapeutics at the World Orphan Drug Congress USA 2019 on April 10-12 in Oxon Hill, Maryland.

Sirnaomics at Opt Congress
March 11, 2019 Sirnaomics to Present at the 4th Annual OPT: Discovery, Development & Delivery

Sirnaomics announced that the Company’s management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery conference on March 25-28, 2019 in Cambridge, Massachusetts.

Sirnaomics AsiaTIDES
February 25, 2019 Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Live

Sirnaomics announced that the Company will present preclinical data from the use of its RNAi technology program in a liver cancer mouse model at AsiaTIDES: Ogligonucleotide & Peptide Therapeutics taking place in Tokyo, Japan on February 28 – March 1, 2019.

1 5 6 7 8 9 12